Business Context and Reporting Period
Company: Outlook Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2026
Reporting Period: Specific event date of June 26, 2026, addressing a listing status matter.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing status.
Material Changes
- Listing Status Resolution: The Company previously received notice on February 18, 2026, of potential delisting from The Nasdaq Capital Market due to failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Compliance Regained: On June 26, 2026, the Company received notification from the Nasdaq Staff that it regained compliance with Nasdaq Listing Rule 5550(a)(2).
- Price Performance: The closing bid price of the Common Stock was at or above $1.00 per share for the ten consecutive business days between June 11, 2026, and June 25, 2026.
- Outcome: The delisting matter is now closed, and the stock remains listed on The Nasdaq Capital Market.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the resolution of the listing deficiency without providing forward-looking financial guidance or operational outlook.
Risks and Contingencies: The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the recent price recovery. No other material risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of Outlook Therapeutics (OTLK) to ensure it remains above the $1.00 threshold to avoid future delisting notices.
- Confirm the stock's continued active listing status on The Nasdaq Capital Market.
- Review the Company's most recent 10-K or 10-Q filings for financial health metrics, as this 8-K contains no financial data.